Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.335
  • Today's Change0.005 / 1.52%
  • Shares traded53.42k
  • 1 Year change-21.18%
  • Beta1.9482
Data delayed at least 20 minutes, as of Feb 10 2026 04:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

INOVIQ Ltd is an Australia-based biotechnology company developing diagnostics and therapeutics for cancer. The Company's commercialized products include EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The Company is also advancing clinical-stage diagnostics for the detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumors.

  • Revenue in AUD (TTM)959.32k
  • Net income in AUD-6.93m
  • Incorporated1983
  • Employees85.00
  • Location
    INOVIQ Ltd23 Normanby Road, Notting HillNEDLANDS 3168AustraliaAUS
  • Phone+61 39548-7586
  • Fax+61 89388-7559
  • Websitehttps://www.inoviq.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TrivarX Ltd1.13m-943.23k25.38m4.00--1.08--22.41-0.0018-0.00180.00230.02040.0923-------7.68-33.47-8.32-37.46-----83.27-373.85---27.050.0132--26.383.8934.25--6.29--
Avecho Biotechnology Ltd1.38m-3.62m36.73m29.00--38.46--26.61-0.0011-0.00110.00040.00030.21154.461.91---55.49-61.23-72.92-73.2762.2755.45-262.41-382.044.53-8.030.0647--139.19-23.209.15------
Vitura Health Ltd124.04m3.28m37.11m119.0010.370.76947.000.29920.00540.00540.20340.07281.6916.4310.46--4.1112.755.7217.6227.2130.972.436.061.059.500.2009--0.1341298.23-5.35--129.38--
Little Green Pharma Ltd38.49m5.86m38.21m--6.460.44423.940.99250.01940.01940.12680.28140.42620.819914.01--6.48--7.09--67.46--15.21--0.8728-4.710.0541--43.67--140.77------
Next Science Ltd31.46m-13.44m42.43m--------1.35-0.046-0.0460.1077-0.00272.075.425.69---88.62-72.67-148.75-86.8782.4877.69-42.74-87.991.25-13.181.12--2.8741.2334.94---18.19--
Inoviq Ltd959.32k-6.93m46.46m85.00--2.20--48.43-0.0623-0.06230.00860.14970.04783.730.6725---34.52-43.01-37.36-45.8787.4589.08-722.62-1,543.445.72--0.022--21.1757.69-5.77------
Medical Developments International Ltd39.06m94.00k53.51m68.00565.480.971116.231.370.00080.00080.34690.48910.62211.065.31--0.1497-16.680.1738-18.9275.3572.700.2407-47.083.33--0.0349--17.8211.30100.23-24.33-34.91--
Neurizon Therapeutics Ltd1.88m-16.59m68.86m52.00--17.75--36.59-0.0334-0.03340.00380.00560.2431--203.57---214.34-65.69-254.22-74.86-----881.68-368.00----0.00-------86.45---44.79--
Data as of Feb 10 2026. Currency figures normalised to INOVIQ Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

8.76%Per cent of shares held by top holders
HolderShares% Held
Merchant Funds Management Pty Ltd.as of 13 Sep 202411.67m8.29%
Netwealth Investments Ltd.as of 01 Sep 2025670.39k0.48%
Data from 09 Dec 2024 - 02 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.